Brexogen and BMI Korea Enter Strategic Technology Transfer Agreement for Exosome Therapeutics
Out-licenses BxC-I17e, Exosome-Based Therapeutics for New Indications KRW 3 Billion Non-Refundable Upfront Payment + Milestone Payments + Double-Digit Percentage Royalties SEOUL, South Korea, Feb. 19, 2025 /PRNewswire/ -- Brexogen, a leading...
SCG Cell Therapy partners A*STAR to accelerate RNA-based therapeutic development in Singapore
SCG Cell Therapy signed a Memorandum of Understanding (MoU) with A*STAR Bioprocessing Technology Institute (A*STAR BTI) and Nucleic Acid Therapeutics Initiative (NATi) to advance ribonucleic acid (RNA)-based therapeutic manufacturing process...